Tag: TSX:BCT

May 14, 2020

BriaCell Announces Presentation and Abstract Publication at 2020 American Society of Clinical Oncology (ASCO) Meeting

New data and pathological findings on BriaCell’s lead candidate, Bria-IMT™, to be Highlighted at ASCO 2020 in a Poster Presentation
May 12, 2020

BriaCell Continues Business and Clinical Operations During COVID-19 Pandemic

BriaCell Therapeutics announces that the Phase I/IIa clinical study of Bria-IMT™, for breast cancer treatment, with Incyte Corporation’s immune checkpoint...
April 27, 2020

BriaCell Files Patent Application for Novel Therapeutics for Cancer

BriaCell Therapeutics (TSXV:BCT) has filed a provisional patent application with the USPTO outlining the development and use of novel therapeutics
April 21, 2020

BriaCell Files New Provisional Patent Application for Antibody-Based Treatment of Infectious Diseases

BriaCell Therapeutics (TSXV:BCT) has filed a provisional patent application with the USPTO outlining the development and use of certain antibodies...
April 14, 2020

BriaCell Files Coronavirus Immunotherapy Patent

BriaCell Therapeutics (TSXV:BCT) announces that it has filed a provisional patent application with the USPTO.
March 31, 2020

BriaCell to Present Clinical Data at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting May 29

BriaCell Therapeutics Corp. announces that it has been selected to present at the 2020 ASCO Annual Meeting.
March 26, 2020

BriaCell Continues Clinical Operations Amidst COVID-19 Pandemic

BriaCell Therapeutics announces that the Phase I/IIa clinical study of Bria-IMT™ with Incyte Corporation’s immune checkpoint inhibitor, is ongoing.